| Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis M Lucijanic, D Galusic, I Krecak, M Sedinic, H Holik, V Perisa, ... Annals of hematology 99, 2779-2785, 2020 | 27 | 2020 |
| Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis M Lucijanić, I Krečak, E Sorić, A Sabljic, D Galušić, H Holik, V Periša, ... Leukemia research 119, 2022 | 12 | 2022 |
| Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis M Lucijanic, I Krecak, D Galusic, M Sedinic, H Holik, V Perisa, ... Wiener klinische Wochenschrift, 1-7, 2021 | 12 | 2021 |
| Ruxolitinib treatment improves muscle mass in patients with myelofibrosis M Lucijanic, D Galusic, E Soric, M Sedinic, M Cubela, R Huzjan Korunic, ... Annals of hematology 100, 1105-1106, 2021 | 10 | 2021 |
| Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis M Lucijanic, I Krecak, E Soric, A Sabljic, D Galusic, H Holik, V Perisa, ... Biochemia medica 33 (2), 2023 | 8 | 2023 |
| Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis M Lucijanic, I Krecak, S Verstovsek, E Soric, D Galusic, H Holik, V Perisa, ... Annals of hematology 101 (6), 1355-1357, 2022 | 7 | 2022 |
| Higher AURKA and PLK1 expression are associated with inferior overall survival in patients with myelofibrosis D Galusic, M Lucijanic, A Livun, M Radman, V Blaslov, LV Cutura, ... Blood Cells, Molecules, and Diseases 81, 102396, 2020 | 5 | 2020 |
| C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis M Lucijanic, D Galusic, I Krecak, M Sedinic, E Soric, H Holik, V Perisa, ... Leukemia & lymphoma 61 (12), 2969-2974, 2020 | 4 | 2020 |
| Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms I Krečak, D Grohovac, NV Bašić, M Čeko, K Nižetić, A Sabljić, H Holik, ... Thrombosis research 231, 141-143, 2023 | 3 | 2023 |
| Nadopuna smjernica za dijagnostiku i liječenje imunosne trombocitopenije u odraslih D Pulanić, S Zupančić-Šalek, A Boban, S Ostojić-Kolonić, D Galušić, ... Bilten Krohema 13, 52-54, 2021 | 3 | 2021 |
| Patterns of glucose fluctuation are challenging in patients treated for non-Hodgkin’s lymphoma A Marić, T Miličević, J Vučak Lončar, D Galušić, M Radman International journal of general medicine, 131-140, 2020 | 3 | 2020 |
| MPN-541 estimated plasma volume status in patients with primary myelofibrosis and Associated Thrombotic and Mortality Risks M Lucijanic, I Krecak, E Soric, A Sabljic, D Galusic, H Holik, V Perisa, ... Clinical Lymphoma Myeloma and Leukemia 22, S341-S342, 2022 | 2 | 2022 |
| Triple A score (AAA: Age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis M Lucijanic, I Krecak, D Galusic, H Holik, V Perisa, M Moric Peric, ... Annals of Hematology, 1-3, 2024 | 1 | 2024 |
| Atrial Fibrillation in Patients with Myelofibrosis M Lucijanic, I Krecak, E Soric, A Sabljic, D Galusic, H Holik, V Perisa, ... Blood 142, 6437, 2023 | 1 | 2023 |
| Dose‐adjusted EPOCH and rituximab (DA‐EPOCH‐R) in older patients with high‐risk aggressive diffuse large B‐cell lymphoma: A real‐life multicenter study by the Croatian … Z Mitrovic, D Dujmovic, O Jaksic, SB Kinda, P Gacina, V Perisa, Z Prka, ... European journal of haematology 110 (6), 725-731, 2023 | 1 | 2023 |
| Efficacy and safety of obinutuzumab-chemotherapy combinations in front-line treatment of follicular non-Hodgkin lymphoma during the COVID-19 pandemic: a study of KROHEM, the … D Galusic, S Basic-Kinda, A Pijuk, V Milunovic, B Dreta, N Franjic, B Coha, ... HemaSphere 6 (12), e807, 2022 | 1 | 2022 |
| Clinical dilemmas in the treatment of elderly patients suffering from Hodgkin lymphoma: a review V Milunović, I Hude, G Rinčić, D Galušić, A Grubešić, M Martinović, ... Biomedicines 10 (11), 2917, 2022 | 1 | 2022 |
| P1040: higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival IN patients with primary myelofibrosis M Lucijanic, I Krecak, E Soric, D Galusic, H Holik, V Perisa, MM Peric, ... HemaSphere 6, 930-931, 2022 | 1 | 2022 |
| Difference between presumed and perceived pain in bone marrow aspiration: pilot study. D Galušić, M Radić, D Lozić, T Brešković Internal medicine journal 47 (6), 2017 | 1 | 2017 |
| Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis M Lucijanic, I Krecak, E Soric, A Sabljic, D Galusic, H Holik, V Perisa, ... Life 14 (4), 523, 2024 | | 2024 |
